Rhythm Pharmaceuticals (RYTM) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $104.0 million.
- Rhythm Pharmaceuticals' Operating Expenses rose 3476.33% to $104.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.5 million, marking a year-over-year decrease of 462.99%. This contributed to the annual value of $395.6 million for FY2024, which is 5112.75% up from last year.
- Per Rhythm Pharmaceuticals' latest filing, its Operating Expenses stood at $104.0 million for Q3 2025, which was up 3476.33% from $93.8 million recorded in Q2 2025.
- Rhythm Pharmaceuticals' 5-year Operating Expenses high stood at $165.9 million for Q1 2024, and its period low was $34.4 million during Q1 2021.
- Moreover, its 5-year median value for Operating Expenses was $65.5 million (2023), whereas its average is $69.0 million.
- Per our database at Business Quant, Rhythm Pharmaceuticals' Operating Expenses skyrocketed by 15914.69% in 2024 and then plummeted by 5194.09% in 2025.
- Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Operating Expenses stood at $52.8 million in 2021, then dropped by 3.62% to $50.9 million in 2022, then increased by 28.7% to $65.5 million in 2023, then grew by 26.85% to $83.1 million in 2024, then grew by 25.11% to $104.0 million in 2025.
- Its Operating Expenses stands at $104.0 million for Q3 2025, versus $93.8 million for Q2 2025 and $79.7 million for Q1 2025.